A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 57
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : IGIV
Long Form : intravenous immunoglobulin
No. Year Title Co-occurring Abbreviation
2019 Cancer-Associated Retinopathy and Treatment with Intravenous Immunoglobulin Therapy. A Seldom Used Approach? CAR
2018 Interventions for necrotizing soft tissue infections in adults. CI, HBO, ICU, IVIG, NSTIs, RCTs, RR
2017 Emerging Paradigm of Primary Immunodeficiency Disease: Individualizing Immunoglobulin Dose and Delivery to Enhance Outcomes. PIDD
2017 Parvovirus B19 infection associated with hemolytic anemia and cranial polyneuropathy. PB19
2016 Demonstration of safety of intravenous immunoglobulin in geriatric patients in a long-term, placebo-controlled study of Alzheimer's disease. ---
2016 FcmuR in human B cell subsets in primary selective IgM deficiency, and regulation of FcmuR and production of natural IgM antibodies by IGIV. MZ, PC, SIGMD
2016 Physical Characterization and Innate Immunogenicity of Aggregated Intravenous Immunoglobulin (IGIV) in an In Vitro Cell-Based Model. FcgammaRs, PBMC
2013 [The role of immunosuppressive agents in Kawasaki disease: a discussion of two cases]. ACA, KD
2012 Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. PI
10  2012 [Stevens-Johnson syndrome and toxic epidermal necrolysis in children]. SJS, TEN
11  2011 Intravenous immunoglobulin modulates the maturation of TLR 4-primed peripheral blood monocytes. DC
12  2010 Information for healthcare providers on general features of IGIV with emphasis on differences between commercially available products. ---
13  2010 The new generation of liquid intravenous immunoglobulin formulations in patient care: a comparison of intravenous immunoglobulins. IgA
14  2010 [Kawasaki disease: Diagnosis and treatment]. CAA
15  2010 [Statistical significance or clinical relevance?]. ---
16  2007 Safety and tolerability of a novel chromatography-based intravenous immunoglobulin when administered at a high infusion rate in patients with immune thrombocytopenic purpura. ITP
17  2007 Safety of IGIV therapy and infusion-related adverse events. IM
18  2006 Intravenous immunoglobulin in autoimmune disorders: an insight into the immunoregulatory mechanisms. ---
19  2006 Pharmacokinetics of intravenous immunoglobulin: a systematic review. ---
20  2006 [Indications for intravenous immunoglobulins]. ---
21  2005 Developing practice guidelines for the administration of intravenous immunoglobulin. ---
22  2005 The patient: Emerging clinical applications of intravenous immunoglobulin. ---
23  2005 The pocketbook: Pharmacoeconomic issues related to intravenous immunoglobulin therapy. IGIV-C
24  2005 The process: New methods of purification and viral safety. ---
25  2005 The product: All intravenous immunoglobulins are not equivalent. ---
26  2004 Gamma irradiation of intravenous immunoglobulin. ---
27  2004 IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life. ITP
28  2004 [Treatment of pemphigus with intravenous immunoglobulin]. ---
29  2003 Evaluation of virus and prion reduction in a new intravenous immunoglobulin manufacturing process. TSE
30  2003 Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%). IgG, SD
31  2002 Polyvisceral arteritis in chronic graft-versus-host disease: antiphospholipid-negative thrombotic syndrome mimicking polyarteritis nodosa. PAN
32  2002 [Intravenous treatment with immunoglobulins in epileptic syndromes which are difficult to control]. CSF, LGS, WS
33  1998 New methods for inactivation of lipid-enveloped and non-enveloped viruses. API, BVDV, kGy, PPV
34  1997 Stability assessment of lyophilized intravenous immunoglobulin after reconstitution in glass containers and poly(vinyl chloride) bags. PVC
35  1997 [Association of plasmapheresis and high doses of intravenous immunoglobulins in the treatment of myasthenia gravis]. MG
36  1996 Cryptogenic partial epilepsies with anti-GM1 antibodies: a new form of immune-mediated epilepsy? CPE, CPS, IGE, MNCB, SCGE, SPE
37  1996 Intravenous immunoglobulin and hepatitis C virus: an overview of transmission episodes with emphasis on manufacturing data. anti-D, HCV, NANB
38  1996 Liver function disturbances in Guillain-Barre syndrome: a prospective longitudinal study in 100 patients. Dutch Guillain-Barre Study Group. PE
39  1996 [Regulation of autoreactivity by the idiotypic network and therapeutic modulation of autoimmunity by polyvalent intravenous immunoglobulins (IgIV)]. ---
40  1995 A prospective study of treatment of acquired (autoimmune) factor VIII inhibitors with high-dose intravenous gammaglobulin. BU
41  1995 [Managing of an innovation in health care: the case of polyvalent intravenous immunoglobulins at the Assistance-Publique-Hopitaux de Paris]. CEDIT
42  1994 Antibody Fc functional activity of intravenous immunoglobulin preparations treated with solvent-detergent for virus inactivation. ---
43  1994 Home infusion of intravenous immunoglobulin. ---
44  1994 Inactivation and elimination of viruses during preparation of human intravenous immunoglobulin. ---
45  1994 Outbreak of hepatitis C associated with intravenous immunoglobulin administration--United States, October 1993-June 1994. FDA, HCV
46  1994 The effect on the safety of intravenous immunoglobulin of testing plasma for antibody to hepatitis C. anti-HCV
47  1993 [Intravenous immunoglobulins (IgIV) in the treatment of autoimmune diseases and systemic inflammatory diseases]. ---
48  1993 [Treatment of immune deficient neuropathies with intravenous polyvalent immunoglobulins. An open study of 16 cases]. ---
49  1992 High-dose intravenous immune globulin in the management of severe Guillain-Barre syndrome. GBS
50  1992 [Intravenous immunoglobulins in hematologic therapy]. ---
51  1991 Guillain-Barre syndrome in a 93-year-old woman: rapid improvement of neurologic function following intravenous immunoglobulin. GBS
52  1991 Prospective study on the hepatitis safety of intravenous immunoglobulin, pH 4.25. NANBH, SGPT
53  1991 The place of high dose immunoglobulins in the treatment of Guillain-Barre patients based upon the dutch trial. PE
54  1991 [Guillain-Barre syndrome treated with high doses of immunoglobulins by the intravenous route: 4 cases]. ---
55  1989 [Therapeutic effectiveness of an intravenous immunoglobulin with pH 4.25 in experimental neonatal sepsis caused by Klebsiella pneumoniae]. PMNs
56  1987 Safety of an intravenous immunoglobulin preparation: lack of seroconversion for human immunodeficiency virus antibodies. AIDS, ELISA, HIV
57  1985 High-dose intravenous IgG in the management of pregnancy in women with idiopathic thrombocytopenic purpura. ITP